TNF Inhibitor denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for TNF Inhibitors — and How to Navigate It

Tumor Necrosis Factor (TNF) inhibitors are high-cost biologic agents, and Aetna — like most major insurers — requires prior authorization (PA) before dispensing. A prior-auth-required denial on a TNF inhibitor typically means one of the following: (1) no PA was submitted before the prescription was filled or the infusion was administered, (2) a PA was submitted but was denied for failure to meet Aetna's clinical criteria, or (3) an existing PA expired and was not renewed before continued therapy.

The appeal path depends on which scenario applies. If the PA was denied on clinical grounds, this is a substantive medical-necessity appeal. If it is an administrative miss (no PA filed, or expired PA), you may be able to resolve it through a retrospective authorization or a corrected submission.

## Federal Appeal Rights

• Internal appeal of PA denial: If your PA request was denied on clinical grounds, file an internal appeal within the deadline on your denial notice. You are entitled to the full utilization-management criteria used and the name and specialty of the reviewing clinician.
• Peer-to-peer review: Before or during the internal appeal, your prescriber may request a peer-to-peer call with the Aetna medical director. This is often the fastest path to a PA reversal and should be pursued promptly.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals, escalate to independent external review within approximately four months of the final adverse determination.
• Expedited review: If your condition is urgent and delay would seriously harm your health, request expedited PA review — the plan must respond within 72 hours.

## What to Gather

• Diagnosis and indication: Chart notes from the prescribing specialist confirming the specific diagnosis and the indication for which the TNF inhibitor is prescribed.
• Prior treatment failure documentation: A dated chronology of all prior conventional and biologic therapies attempted, with outcomes and reasons for discontinuation, as required by Aetna's PA criteria.
• Disease severity measures: Current chart documentation — validated scoring tools, lab trends, imaging findings — showing your current level of disease activity.
• Prescriber PA letter: A letter from your specialist directly addressing each item in Aetna's published PA criteria for the specific TNF inhibitor, with chart citations.
• Applicable guideline support: Reference to the relevant specialty society guideline organization (e.g., ACR, AGA) supporting biologic initiation at your stage of disease.

## Criteria-Mapping Structure

Download Aetna's Clinical Policy Bulletin for the specific TNF inhibitor you were prescribed. List every prior-authorization criterion. For each criterion, your prescriber's letter should cite the specific chart entry, date, and finding that satisfies it. A complete, criterion-by-criterion response — rather than a narrative letter — is the format most likely to result in approval at the PA or first-level appeal stage.